AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
4,997.00
+6.00 (+0.12%)
As of 8:41AM BST. Market open.
Stock chart is not supported by your current browser
Previous Close4,991.00
Open5,009.00
Bid4,996.50 x 6100
Ask4,997.50 x 13000
Day's Range4,996.00 - 5,017.00
52 Week Range4,260.00 - 5,520.00
Volume159,367
Avg. Volume2,458,462
Market Cap63.292B
Beta0.98
PE Ratio (TTM)21.08
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.02 (4.12%)
Ex-Dividend Date2018-02-15
1y Target EstN/A
  • Reuters2 days ago

    AstraZeneca raises stake in respiratory partner Circassia

    By Paul Sandle LONDON (Reuters) - AstraZeneca (AZN.L) is paying up to $45 million (32.25 million pounds) to increase its stake in Circassia (CIRCI.L), backing a company seeking to bounce back from the ...

  • The Wall Street Journal2 days ago

    [$$] Third Rock Throws Support Behind New Biotech Player

    Faslodex degrades estrogen receptors to treat breast cancer. Early this month Arvinas took in $55 million to develop protein-degrading treatments for prostate and breast cancer. Cambridge, Mass.-based Cedilla is capitalizing on growing understanding of the principles governing protein stability to identify protein-degrading therapies.

  • Reuters2 days ago

    AstraZeneca flop a fresh blow to cancer immunotherapy combination

    The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company's experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.

  • Reuters2 days ago

    AstraZeneca third-line lung cancer combination study fails

    A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping ...

  • FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
    Zacks3 days ago

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)

    Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks6 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
    Zacks7 days ago

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

    AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

  • Reuters7 days ago

    AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

    U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday. The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

  • Industry fears disruption as EU excludes UK from drug approvals
    Reuters8 days ago

    Industry fears disruption as EU excludes UK from drug approvals

    A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients. The move confounds hopes for continued joint cooperation via the European Medicines Agency (EMA), at least during a transition or implementation period until the end of 2020 when the UK will remain closely tied to the European Union. Prime Minister Theresa May said in a speech on March 2 that London wanted to explore ways to keep Britain a part of EU agencies, such as the EMA.

  • An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued
    Simply Wall St.9 days ago

    An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued

    How far off is AstraZeneca PLC (LSE:AZN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...

  • Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
    Zacks15 days ago

    Spectrum Pharma Stock Up on Positive Lung Cancer Study Data

    Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.

  • Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
    Zacks15 days ago

    Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

    Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

  • Top Analyst Reports for Microsoft, Merck & Union Pacific
    Zacks16 days ago

    Top Analyst Reports for Microsoft, Merck & Union Pacific

    Top Analyst Reports for Microsoft, Merck & Union Pacific

  • MarketWatch17 days ago

    Ionic Pharmaceuticals shares jump 3% premarket on news of license deal with AstraZeneca

    Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis ...

  • Reuters17 days ago

    Ionis to get up to $300 mln from licensing deal with AstraZeneca

    Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties. ...

  • Reuters17 days ago

    South Africa may ask pharma firms for fee to clear drug review backlog

    Drugmakers in Africa's largest pharmaceutical market may be asked to pay a "backlog fee" to help clear a pipeline of medicines waiting years for approval, according to a proposal being considered by South Africa's new industry regulator. Delays for hundreds of medicines have kept the latest treatments off South African shelves and hampered the fight against cancer, heart and other diseases in a country which also has more people receiving anti-retroviral drugs (ARVs) than anywhere else in the world. "It's the first time South Africa offers this and we would support a backlog fee, provided it is performance driven," said Stavros Nicolaou, senior executive for strategic trade at Aspen Pharmacare.

  • Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
    Zacks20 days ago

    Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

    Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

  • 3 Emerging Technologies Set to Transform the Pharma World
    Zacks21 days ago

    3 Emerging Technologies Set to Transform the Pharma World

    Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.

  • Pfizer Has Big Plans in Treating Lung Cancer
    Motley Fool21 days ago

    Pfizer Has Big Plans in Treating Lung Cancer

    The filing for approval of two new lung cancer drugs positions the company to increase its market share in the indication.

  • AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
    Zacks22 days ago

    AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use

    AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.

  • Reuters22 days ago

    PRESS DIGEST- Financial Times - April 4

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines WPP probes misconduct allegation against Sorrell https://on.ft.com/2GuttQE ...

  • Reuters23 days ago

    UK Stocks-Factors to watch on April 3

    (Adds company news items and futures) April 3 (Reuters) - Britain's FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers, with futures down 1.15 percent ...

  • Reuters23 days ago

    Deals of the day-Mergers and acquisitions

    (Adds Elliott, COFCO Property, ReNew Power, General Electric; Updates Transcontinental) April 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ...

  • Reuters24 days ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.